{
    "name": "patisiran",
    "comment": "Rx",
    "other_names": [
        "Onpattro"
    ],
    "classes": [
        "RNAi Agents"
    ],
    "source": "https://reference.medscape.com/drug/onpattro-patisiran-1000238",
    "pregnancy": {
        "common": [
            "There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed during pregnancy; physicians are encouraged to enroll pregnant patients, or pregnant women may register themselves in the program by calling 1-877-256-9526 or by contacting alnylampregnancyprogram@iqvia.com",
            "No data are available on use in pregnant women to inform a drug-associated risk of adverse developmental outcomes",
            "Treatment leads to a decrease in serum vitamin A levels, and vitamin A supplementation is advised; vitamin A is essential for normal embryofetal development; however, excessive levels of vitamin A are associated with adverse developmental effects; effects on the fetus of a reduction in maternal serum transthyretin caused by therapy and of vitamin A supplementation are unknown"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal studies, intravenous administration of patisiran lipid complex (patisiran-LC) to pregnant rabbits resulted in developmental toxicity (embryofetal mortality and reduced fetal body weight) at doses that were also associated with maternal toxicity; no adverse developmental effects were observed when patisiran-LC or a rodent-specific (pharmacologically active) surrogate was administered to pregnant rats"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information regarding presence of drug in human milk, effects on breastfed infant, or on milk production",
            "Consider developmental and health benefits of breastfeeding along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from the underlying maternal condition",
            "In lactating rats, patisiran was not detected in milk; however, lipid components (DLin-MC3-DMA and PEG2000-CDMG) were present in milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Infusion-related reactions",
                    "description": [
                        "Infusion-related reactions (IRRs) observed in patients receiving therapy",
                        "The most common symptoms reported include flushing, back pain, nausea, abdominal pain, dyspnea, and headache; severe hypotension and syncope reported as symptoms of IRRs in the expanded access program and postmarketing setting",
                        "Patients should receive premedications on day of infusion, at least 60 min prior to infusion; monitor patients during infusion for signs and symptoms of IRRs; if IRR occurs, consider slowing or interrupting infusion and instituting medical management (eg, corticosteroids or other symptomatic treatment), as clinically indicated (see Dosing)",
                        "If infusion interrupted, consider resuming at slower infusion rate only if symptoms have resolved; in case of a serious or life-threatening IRR, infusion should be discontinued and not resumed",
                        "Some patients may benefit from slower infusion rate or, additional or higher doses of other premedications with subsequent infusions to reduce risk",
                        "Severe hypotension and syncope reported as symptoms of IRRs"
                    ]
                },
                {
                    "type": "Reduced serum vitamin A levels and recommended supplementation",
                    "description": [
                        "May decrease serum vitamin A levels",
                        "Vitamin A supplementation advised; higher doses than recommended daily allowance of vitamin A should not be given to try to achieve normal serum vitamin A levels during treatment; serum vitamin A levels do not reflect total vitamin A in the body",
                        "Refer to ophthalmologist if patient develops ocular symptoms of vitamin A deficiency (eg, night blindness)"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Upper respiratory tract infections",
            "percent": "29"
        },
        {
            "name": "Infusion",
            "percent": "19"
        },
        {
            "name": "related reaction",
            "percent": "8"
        },
        {
            "name": "Dyspepsia",
            "percent": "8"
        },
        {
            "name": "Dyspnea",
            "percent": "8"
        },
        {
            "name": "Muscle spasms",
            "percent": "7"
        },
        {
            "name": "Arthralgia",
            "percent": "7"
        },
        {
            "name": "Erythema",
            "percent": "7"
        },
        {
            "name": "Bronchitis",
            "percent": "5"
        },
        {
            "name": "Vertigo",
            "percent": "3"
        },
        {
            "name": "Blurred vision",
            "percent": "2.7"
        },
        {
            "name": "AV heart block",
            "percent": "2"
        },
        {
            "name": "Vitreous floaters",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Extravasation",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        }
    ]
}